Alumis eyes late-stage lupus study despite trial miss


Save Story

Estimated read time: 1-2 minutes

Sept 1 — Alumis said on Tuesday it plans to advance its experimental drug for a ​type of immunity-related condition in a smaller subset of patients, even after the treatment failed to meet the main goal of ‌a mid-stage trial.

Its shares slumped more than 55% in premarket trading, as Wall Street had viewed ⁠the study as an important ​test in a disease long seen ⁠as a drug-development graveyard.

Here are some details:

• The drug developer focused on ‌autoimmune diseases was ‌testing the oral treatment, envudeucitinib, in 408 adults with moderate-to-severe systemic ⁠lupus erythematosus (SLE) over 48 weeks to ⁠see if it could significantly ease the symptoms.

• Despite the trial's failure to meet its main goal, the San Francisco-based company said it plans to talk with regulators about starting a late-stage trial.

• Alumis said a specific subgroup of patients with higher interferon activity, a ‌marker linked to lupus severity, showed strong improvement, ​including on the study's main measure of disease activity.

• According to the company, these patients are thought to respond better to therapies targeting the interferon pathway and made up a smaller share of the trial population than expected, which Alumis said contributed to the overall study miss.

• The drug, which works by blocking a key immune-system protein ​called TYK2 to calm the overactive inflammation, was generally well tolerated and showed ‌no new safety ‌concerns during ⁠the study.

• Over 200,000 people in the U.S. are estimated to have SLE, according to the Centers for Disease Control and Prevention.

• Alumis also said it remains on track to file for U.S. regulatory approval of the ‌drug to treat moderate-to-severe ​plaque psoriasis, a skin condition, in the ‌fourth quarter of 2026 ⁠after previously reporting ​positive trial results.

(Reporting by Kamal Choudhury in Bengaluru; Editing by Leroy Leo and ​Shilpi Majumdar)

Most recent Lifestyle stories

Related topics

STAY IN THE KNOW

Get informative articles and interesting stories delivered to your inbox weekly. Subscribe to the KSL.com Trending 5.
By subscribing, you acknowledge and agree to KSL.com's Terms of Use and Privacy Notice.
Newsletter Signup

KSL Weather Forecast

KSL Weather Forecast
Play button